Shandong Boan Biotechnology Co., Ltd. (FRA:UJ9)

Germany · Delayed Price · Currency is EUR

0.5000

-0.0050 (-0.99%)

At close: Jun 26, 2026

-62.96% (1Y)

Market Cap	315.21M -55.2%
Revenue (ttm)	95.57M +8.1%
Net Income	869.92K -90.2%
EPS	0.00 -90.9%
Shares Out	n/a
PE Ratio	362.35
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.4920
Previous Close	0.5050
Day's Range	0.4920 - 0.5050
52-Week Range	0.4980 - 2.1200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About FRA:UJ9

Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of post... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2013

Employees 696

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol UJ9

Financial Performance

In 2025, FRA:UJ9's revenue was 784.82 million, an increase of 8.06% compared to the previous year's 726.32 million. Earnings were 7.14 million, a decrease of -90.24%.

Financial numbers in CNY Financial Statements